3월 31일 15:40

GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan

GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare...

1월 31일 17:24

GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand

GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 2...

2024년 12월 2일 14:15

GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical

GE HealthCare (Nasdaq: GEHC) has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing from Sumitomo Chemical (TYO: 4005) the 50% stake it does not already own. As part of GE HealthCare, NMP can build on its expertis...

2024년 10월 8일 08:37

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

GE HealthCare (Nasdaq: GEHC) has today announced the completion of its Phase I clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. The results, which will be used to sup...

2023년 11월 3일 09:10

GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

GE HealthCare’s Artificial Intelligence (AI) models predict patient response to immunotherapies with 70 to 80 percent accuracy[1], based on a pan-cancer cohort, according to findings to be presented at the Society for Immunotherapy of Cancer (SITC...

2023년 10월 12일 13:31

SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibro...

2023년 6월 15일 15:38

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

With immunotherapy emerging as one of the most important treatment options in oncology, GE HealthCare has today announced the first patient scanned in a Phase I clinical trial[2] of a first-of-its kind fluorine-18 PET radiopharmaceutical ([18F]GEH...

2023년 3월 2일 11:15

GE HealthCare Announces Completion of Phase I Subject Recruitment in Early Clinical Development Program for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

GE HealthCare has today announced, at the European Congress of Radiology (ECR) in Vienna, Austria, the completion of Phase I subject recruitment in its early clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic...

2022년 11월 18일 14:30

GE Healthcare Announces $80 Million Investment To Expand Contrast Media Production Capacity

GE Healthcare’s Pharmaceutical Diagnostics business announced an $80 million investment to increase manufacturing capacity by 30 percent at its Active Pharmaceutical Ingredients (API) site in Lindesnes, Norway. The investment - which is creating a...

2022년 10월 14일 09:35

GE Healthcare Announces Multi-Year Agreement with SQM to Secure Iodine Supply for Contrast Media

GE Healthcare’s Pharmaceutical Diagnostics business has announced a long-term agreement with Chile-based mining company, Sociedad Quimica y Minera de Chile S.A. (SQM) (NYSE: SQM; Santiago Stock Exchange: SQM-B, SQM-A), to secure its supply of iodi...

2022년 9월 14일 13:55

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both se...

2019년 1월 7일 10:15

GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment

GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will be developed to help predict both the efficacy of an immu...

2018년 1월 8일 16:55

GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment

GE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerat...

2017년 6월 13일 11:55

Kieran Murphy Appointed CEO of GE Healthcare, Succeeding John Flannery

GE Chairman and CEO Jeff Immelt announced today the appointment of Kieran Murphy as president and CEO of GE Healthcare, effective immediately. Murphy is currently president and CEO of GE Healthcare Life Sciences. Murphy succeeds John Flannery who ...

2017년 6월 13일 11:55

키어런 머피, 존 플래너리에 이어 GE 헬스케어 CEO로 임명

GE 회장 겸 최고경영자(CEO) 제프 이멜트(Jeff Immelt)가 GE 헬스케어(GE Healthcare) 사장 겸 CEO로 키어런 머피(Kieran Murphy)를 임명했으며 즉시 효력이 발생한다고 12일 발표했다. 머피는 현재 ‘GE 헬스케어 라이프 사이언스(GE Healthcare Life Sciences)의 사...

2016년 7월 14일 17:15

Investing in Cures for Cancer: GE Poised to Lead Industrialization of Cell Therapy Industry with Acquisition of Biosafe Group SA

GE Healthcare has acquired Biosafe Group SA, a supplier of integrated cell bioprocessing systems for the rapidly growing cell therapy and regenerative medicine industry for an undisclosed sum. The acquisition of Biosafe expands GE Healthcare’s end...

2016년 7월 14일 17:15

암치료 투자: GE, 바이오세이프 그룹 인수로 세포치료 산업화 주도

GE 헬스케어(GE Healthcare)가 빠르게 성장하는 세포치료 및 재생의학 산업에 통합 세포 바이오처리 시스템을 공급하는 바이오세이프 그룹(Biosafe Group SA)을 인수했다. 인수금액은 밝히지 않았다. 바이오세이프의 인수는 세포치료를 위한 GE 헬스케어의 제품과 솔...

2016년 5월 11일 13:15

JHL Biotech Opens Innovative Biosimilars Manufacturing Facility in China

JHL Biotech (JHL), a biopharmaceutical company, opened the world’s first KUBio™ biopharmaceutical manufacturing facility with single-use bioprocessing technology at a ribbon-cutting ceremony in Wuhan, China today. JHL will use the KUBio manufactur...

2016년 5월 11일 13:15

JHL 바이오테크, 중국에 혁신적인 바이오시밀러 제조시설 설립

생물약제 기업인 JHL 바이오테크(JHL Biotech, 이하 JHL)가 오늘 중국 우한에서 열린 개설식에서 일회용 바이오프로세싱 기술을 이용한 세계 최초의 KUBio™ 생물약제 제조시설을 열었다. JHL은 GE 헬스케어(GE Healthcare)가 제공하는 KUBio 제조 솔루션을 이용해 말...

2016년 1월 13일 23:45

GE Healthcare, FedDev Ontario Commit CAD $40M for New CCRM-Led Centre to Solve Cell Therapy Manufacturing Challenges

GE Healthcare, the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and the Centre for Commercialization of Regenerative Medicine (CCRM) are building a centre for advanced therapeutic cell technologies in Toronto with an ...

2016년 1월 13일 23:45

GE 헬스케어, 치료세포 제작 문제 해결 위해 CCRM이 주도하는 기술센터 건립에 FedDev 온타리오와 4000만 캐나다 달러 출연

GE 헬스케어(GE Healthcare), 남부 온타리오 연방경제개발국(Federal Economic Development Agency for Southern Ontario, 이하 FedDev 온타리오), 그리고 캐나다 재생의학 상업화센터(Centre for Commercialization of Regenerative Medicine, 이하 CCRM)가 토론토(...

2014년 7월 1일 11:40

CHMP Recommends EU Approval of VIZAMYL™ (Flutemetamol F18 Injection) for PET Imaging of Beta Amyloid Plaque

GE Healthcare today announced the receipt of a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). This opinion recommends the granting of a marketing authorisation for VIZAMYL™ (Flutemetamo...

2014년 7월 1일 11:40

CHMP, 베타 아밀로이드 신경반의 PET 촬영용 의약품인 VIZAMYL™ (플루테메타몰 F18 주사제)에 대한 EU의 승인 권고

GE 헬스케어(GE Healthcare)는 오늘 유럽의약품청(European Medicines Agency, EMA) 약물사용자문위원회(Committee for Medicinal Products for Human Use, CHMP)로부터 긍정적인 의견서를 접수했다고 발표했다. 이 의견서는 알츠하이머병(AD) 및 기타의 원인으로 인...

2014년 1월 7일 12:55

GE To Expand in Life Sciences with Acquisition of Strategic Assets from Thermo Fisher Scientific

GE (NYSE:GE) and Thermo Fisher Scientific (NYSE:TMO) announced today that they have entered into an agreement for GE Healthcare to acquire Thermo Fisher’s HyClone™ cell culture media and sera, and gene modulation and magnetic beads businesses for ...

2014년 1월 7일 12:55

GE, 써모 피셔 사이언티픽의 전략적 자산 인수 통해 생명과학 부문 확대

GE (뉴욕증권거래소:GE)와 써모 피셔 사이언티픽 (Thermo Fisher Scientific, 뉴욕증권거래소:TMO)는 오늘 GE 헬스케어 (GE Healthcare)가 써모 피셔의 하이클론 (HyClone™) 세포배양 배지 및 혈청, 유전자 조절, 자성입자 사업을 약 10억 6,000만 달러에 인수하기로...